New drug HLX42 targets tough cancers in first human trial
NCT ID NCT06210815
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 25 times
Summary
This early-stage study tests a new drug called HLX42 in people with advanced solid tumors, including lung cancer, that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 102 participants will receive the drug to see how well it is tolerated and how it works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR AND NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangdong, Guangzhou, China
Contact
Conditions
Explore the condition pages connected to this study.